Menu
Recruiting NCT07009067

Safety and Efficacy of Exercise in Type-B Aortic Dissection

No phase Interventional Type B Aortic Dissection

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Exercise-based Cardiac Rehabilitation.
Who it may be relevant to
Registry conditions: Type B Aortic Dissection. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Safety and Efficacy of Cardiac Rehabilitation With Exercise in Patients With Type-B Aortic Dissection and Intervention: Pilot Study

Overview

This is a pilot study. The goal of this clinical trial is to evaluate the safety and efficacy of exercise-based cardiac rehabilitation in patients with Type-B Aortic dissection or intramural hematoma or penetrating ulcer and received endovascular repair. The main questions it aims to answer are: • Is exercise-based cardiac rehabilitation safe among these patients? Participants will be randomly assigned to receive usual care plus exercise-based cardiac rehabilitation (guided exercise for 3 months in rehabilitation center) or usual care.

Interventions

  • Behavioral Exercise-based Cardiac Rehabilitation
    Participated will receive 36 individualized Exercise-based Cardiac Rehabilitation after enrollment in our Cardiac Rehabilitation Center.

Primary outcome measures

  • Adverse events during exercise [Time frame: 3 months]
  • Aortic diameter [Time frame: 3 months]
  • Progression of dissection [Time frame: 3 months]
  • Endoleak [Time frame: 3 months]

Eligibility criteria

Inclusion criteria

  • Patients with a previous diagnosis of type B aortic dissection or intramural hematoma or penetrating ulcer, who underwent endovascular aortic repair (EVAR) or EVAR + supra-aortic shunt surgery for more than 1 month, and no related complications (such as endoleak, stent thrombosis, dissection progression, etc.) were found in the postoperative aortic CTA;
  • Able to independently carry out basic daily life activities, participants must be able to complete the baseline assessment and start the designated treatment;
  • Patients voluntarily participate in this study, sign the written informed consent, and are willing to cooperate with the follow-up;

Exclusion criteria

  • Acute myocardial infarction occurred 1 month ago;
  • Combined with severe aortic stenosis or regurgitation;
  • Combined with ascending aortic aneurysm or dissection;
  • Acute heart failure occurred 2 weeks ago;
  • Combined with severe hypertrophic obstructive cardiomyopathy;
  • Chronic renal failure stage 5, which is defined as glomerular filtration rate <15ml/(min·1.73m2) or dialysis;
  • During the screening examination, the patient's alanine aminotransferase or aspartate aminotransferase is greater than or equal to 5 times the upper limit of the normal value specified by our center;
  • Patients with any medical history that may affect compliance with the program;
  • Patients with severe language, mental or physical disabilities who are unable to participate in the program;
  • Pregnant or lactating women, or those with fertility who are unwilling/unable to take effective contraceptive measures;
  • Patients participating in other interventional clinical trials;
  • Patients with long-term high-intensity exercise habits;
  • Patients who are judged by the researchers to be unsuitable for participation in this study;

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

China · 1 center
  • Guangdong Provincial People's Hospital — Guangzhou

Identifiers

NCT: NCT07009067 · KY2025-203

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗